$MEIファーマ(MEIP.US)$ NEWS MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients MEI Pharma, Inc. reports positive results from the ongoing Phase 1b study of ME-344 in combination with bevacizumab for relapsed metastatic colorectal cancer. 25% of patients had no disease progression at Week 16, exceeding the threshold to add more patients. The combination was well-tolerated, leading to the...
MEIファーマに関するコメント
NEWS
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
MEI Pharma, Inc. reports positive results from the ongoing Phase 1b study of ME-344 in combination with bevacizumab for relapsed metastatic colorectal cancer. 25% of patients had no disease progression at Week 16, exceeding the threshold to add more patients. The combination was well-tolerated, leading to the...
$ゴッサマー バイオ(GOSS.US)$ $Starry Group(STRY.US)$ $Helbiz(HLBZ.US)$ $MEIファーマ(MEIP.US)$ $デジタル ブラン(DBGI.US)$ $コスモス ホールディング(COSM.US)$ $コムソブリン・ホールディング(COMS.US)$ $Mirati Therapeutics(MRTX.US)$ $ユナイテッド パーセル サービス B(UPS.US)$ $Sumo Logic(SUMO.US)$
wherr is thr link for earnings
Tomorrow to the 🚀🌕
https://www.etfdailynews.com/2022/05/02/mei-pharma-inc-nasdaqmeip-sees-significant-increase-in-short-interest/
Finally
まだコメントはありません